- €304.66m
- €1.24bn
- $1.08bn
- 40
- 85
- 25
- 46
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,357 | 887 | 1,063 | 927 | 1,076 |
Cost of Revenue | |||||
Gross Profit | 390 | 160 | 210 | 273 | 258 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,113 | 1,060 | 1,086 | 746 | 957 |
Operating Profit | 244 | -173 | -23.2 | 182 | 119 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 117 | -347 | -186 | 83.5 | 19.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | 126 | -376 | -182 | 66.3 | 5.9 |
Minority Interest | |||||
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -69.1 | -441 | -181 | 43.1 | 12.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -69.1 | -441 | -181 | 43.1 | 14.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.175 | -0.384 | -0.142 | 0.044 | 0.002 |
Dividends per Share |